We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
New Tissue Microarrays Conform with FDA Standards
Product News

New Tissue Microarrays Conform with FDA Standards

New Tissue Microarrays Conform with FDA Standards
Product News

New Tissue Microarrays Conform with FDA Standards

Image credit: AMSBIO

Want a FREE PDF version of This Product News?

Complete the form below and we will email you a PDF version of "New Tissue Microarrays Conform with FDA Standards"

First Name*
Last Name*
Email Address*
Country*
Company Type*
Job Function*
Would you like to receive further email communication from Technology Networks?

Technology Networks Ltd. needs the contact information you provide to us to contact you about our products and services. You may unsubscribe from these communications at any time. For information on how to unsubscribe, as well as our privacy practices and commitment to protecting your privacy, check out our Privacy Policy

AMSBIO offers an unmatched portfolio of over 2000 tissue microarrays (TMAs), one of the best sample formats for rapid detection of cellular localization of RNA and protein expression.

Recently AMSBIO introduced US Food & Drug Administration (FDA) standard TMAs for human, mouse and rat to its portfolio. Designed in close conformance with FDA guidelines, this range meets the requirements for tissue cross-reactivity studies required for therapeutic and diagnostic antibody and antibody-like molecules validation. Each array slide features the FDA recommended list of normal tissue types in triplicate, allowing the identification of off-target binding and on-target binding that has not been previously identified.

Tissue microarray slides offer a rapid and cost-effective direct method for the validation of biological targets in multiple tissue samples. Parallel analysis of multiple specimens reduces operating times, conserves reagents and facilitates high-throughput molecular analysis of tissues.

The new FDA standard TMAs form part of AMSBIO’s broad collection of normal and tumor TMAs available in FFPE and frozen formats. Produced using high-quality tissue samples selected by board-certified pathologists, TMAs are a remarkable tool with a range of potential applications in basic research, prognostic oncology and drug discovery.
Advertisement